公开(公告)号：US20210038732A1

公开(公告)日：2021-02-11

申请号：US16966869

申请日：2019-02-12

Applicant: INTERNA TECHNOLOGIES B.V.

Inventor： Matheus Maria DE GUNST ,  Laurens Adrianus Hendricus VAN PINXTEREN ,  Michel JANICOT ,  Iman Johannes SCHULTZ ,  Roeland Quirinus Jozef SCHAAPVELD ,  Sanaz YAHYANEJAD

IPC: A61K47/54 ,  A61K47/69 ,  A61K31/7105 ,  A61K31/221 ,  A61K31/355

Abstract: The present invention relates to a lipid formulation comprising microRNA. The formulation comprises cationic lipids that can form lipid nanoparticles with the microRNA. The formulations are useful in medicine.

公开(公告)号：US20170130277A1

公开(公告)日：2017-05-11

申请号：US15319452

申请日：2015-06-19

Applicant: STICHTING VU-VUMC ,  INTERNA TECHNOLOGIES B.V.

Inventor： Gerrit Albert MEIJER ,  Begoña DIOSDADO ,  Lisette M. TIMMER ,  Edwin Pieter Johan Gerard CUPPEN ,  Eugene BEREZIKOV ,  Francesco CERISOLI ,  Roeland Quirinus Jozef SCHAAPVELD

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/158 ,  C12Q2600/16 ,  C12Q2600/178

Abstract: Methods of diagnosing colorectal cancer and precursors thereof using miRNA biomarkers are disclosed, together with kits and devices for detecting the biomarkers, and uses of the biomarkers. The biomarkers described are reliably detected in stool and demonstrate significantly different expression levels in colorectal cancer patients when compared to colorectal cancer negative patients.

公开(公告)号：US20140005251A1

公开(公告)日：2014-01-02

申请号：US13933526

申请日：2013-07-02

Applicant: InteRNA Technologies B.V.

Inventor： Sanne WEIJZEN ,  Roeland Quirinus Jozef SCHAAPVELD ,  Meriem BOURAJJAJ ,  Rick Jan VAN HAASTERT ,  Arjan Willem GRIFFIOEN ,  Judith Rosina VAN BEIJNUM ,  Edwin Pieter Johan Gerard CUPPEN ,  Eugene BEREZIKOV ,  Andreas Alphons Franciscus Ludovicus VAN PUIJENBROEK ,  Willemijn Maria GOMMANS ,  Negar BABAE ,  Petronella Innocentia VAN NOORT

IPC: C12N15/113 ,  C12Q1/68

CPC classification number: C12N15/1135 ,  A61P35/00 ,  C12N7/00 ,  C12N15/113 ,  C12N2310/141 ,  C12N2320/10 ,  C12N2320/11 ,  C12N2320/30 ,  C12N2320/31 ,  C12N2710/10043 ,  C12N2740/15043 ,  C12Q1/6883 ,  C12Q1/6886

Abstract: The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a disease and condition associated with neo-angiogenesis.

Abstract translation: 本发明涉及在与新血管生成相关的疾病和病症中的miRNA分子，其等同物或来源的诊断和治疗用途。

公开(公告)号：US20230136088A1

公开(公告)日：2023-05-04

申请号：US17904864

申请日：2021-02-26

Applicant: INTERNA TECHNOLOGIES B.V.

Inventor： Sanaz YAHYANEJAD ,  Bryony TELFORD ,  Marion VAN DEN BOSCH ,  Mir Farshid ALEMDEHY ,  Matheus Maria DE GUNST ,  Laurens Adrianus Hendricus VAN PINXTEREN ,  Roeland Quirinus Jozef SCHAAPVELD ,  Michel JANICOT

IPC: C12N15/113 ,  A61K31/7105 ,  A61P35/00

Abstract: The invention relates to the use of miRNA-193a for regulating gene expression, particularly it relates to the use of miRNA-193a as a CRT agonist, promoting the cell surface expression of CRT. This allows the advantageous treatment of cancers without or with low surface expression of CRT. The invention further relates to compositions comprising the miRNA for use in such treatment.

公开(公告)号：US20210315917A9

公开(公告)日：2021-10-14

申请号：US16760396

申请日：2018-11-02

Applicant: INTERNA TECHNOLOGIES B.V.

Inventor： Eljo Y. VAN BATTUM ,  Vamshi R. VANGOOR ,  Alwin A.H.A. DERIJCK ,  Roeland Quirinus Jozef SCHAAPVELD ,  R. Jeroen PASTERKAMP

IPC: A61K31/713 ,  C12N15/113

Abstract: The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a neuronal deficiency or a disease and condition associated with neuronal deficiency.

公开(公告)号：US20220275368A1

公开(公告)日：2022-09-01

申请号：US17630457

申请日：2020-03-06

Applicant: INTERNA TECHNOLOGIES B.V.

Inventor： Sanaz YAHYANEJAD ,  Bryony Jane TELFORD ,  Marion Tina Jolien VAN DEN BOSCH ,  Mir Farshid ALEMDEHY ,  Matheus Maria DE GUNST ,  Laurens Adrianus Hendricus VAN PINXTEREN ,  Roeland Quirinus Jozef SCHAAPVELD ,  Michel JANICOT

IPC: C12N15/113 ,  A61P35/00 ,  A61K45/06

Abstract: The invention relates to the use of miRNA-193a for regulating gene expression, particularly it relates to the use of miRNA-193a as a PTEN agonist. This allows the advantageous treatment of PTEN-deficient cancers. The invention further relates to compositions comprising the miRNA for use as a PTEN agonist.

公开(公告)号：US20160333353A1

公开(公告)日：2016-11-17

申请号：US15227832

申请日：2016-08-03

Applicant: INTERNA TECHNOLOGIES B.V.

Inventor： Sanne WEIJZEN ,  Roeland Quirinus Jozef SCHAAPVELD ,  Meriem BOURAJJAJ ,  Rick Jan VAN HAASTERT ,  Arjan Willem GRIFFIOEN ,  Judith Rosina VAN BIEJNUM ,  Edwin Pieter Johan Gerard CUPPEN ,  Eugene BEREZIKOV ,  Andreas Alphons Franciscus Ludovicus VAN PIUJENBROEK ,  Willemijn Maria GOMMANS ,  Negar BABAE ,  Petronella Innocentia VAN NOORT

IPC: C12N15/113 ,  C12N7/00 ,  C12Q1/68

CPC classification number: C12N15/1135 ,  A61P35/00 ,  C12N7/00 ,  C12N15/113 ,  C12N2310/141 ,  C12N2320/10 ,  C12N2320/11 ,  C12N2320/30 ,  C12N2320/31 ,  C12N2710/10043 ,  C12N2740/15043 ,  C12Q1/6883 ,  C12Q1/6886

Abstract: The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a disease and condition associated with neo-angiogenesis.

Abstract translation: 本发明涉及在与新血管生成相关的疾病和病症中的miRNA分子，其等同物或来源的诊断和治疗用途。

公开(公告)号：US20160017338A1

公开(公告)日：2016-01-21

申请号：US14849777

申请日：2015-09-10

Applicant: INTERNA TECHNOLOGIES B.V.

Inventor： Roeland Quirinus Jozef SCHAAPVELD ,  Gerardus Wilhelmus Christiaan Theodoor VERHAEGH ,  Jacobus Antonius SCHALKEN ,  Andreas Alphons Franciscus Ludovicus van PUIJENBROEK ,  Willemijn Maria GOMMANS ,  Sanne WEIJZEN

IPC: C12N15/113 ,  A61K45/06 ,  A61N5/10 ,  A61K31/713

CPC classification number: C12N15/1138 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/713 ,  A61K45/06 ,  A61N5/10 ,  C12N15/113 ,  C12N2310/141 ,  C12N2320/31 ,  C12N2330/10

Abstract: The invention relates to the diagnostic and therapeutic uses of a miRNA molecule or an equivalent thereof wherein a source of said miRNA molecule or equivalent thereof comprises at least 80 nucleotides and comprises a motif having at least 98% identity with the motif represented by SEQ ID NO:1 or a source thereof in a disease and condition associated with EMT (Epithelial to Mesenchymal Transition).